What is convalescent plasma therapy?
What do we know thus far about convalescent plasma therapy in COVID-19 illness?
Why do we need more RCTs of convalescent plasma?
Can we rapidly provide convalescent plasma with neutralising antibodies during a pandemic?
What are the key design issues to consider in RCTs of convalescent plasma?
Trial ID [country] | Participants | Intervention | Comparator | Outcome | N |
---|---|---|---|---|---|
ChiCTR2000029757 [China] | Severely ill/critically ill | Volume = NR | Standard of care | 2-point improvement in clinical symptoms in a 6-point scale | 200 |
Titres = NR | |||||
ChiCTR2000030010 [China] | Severely ill adults less than 70 years | Volume = NR | Ordinary plasma | 2-point improvement in clinical symptoms in a 6-point scale | 100 |
Titres = NR | |||||
ChiCTR2000030179 [China] | Severely ill adults less than 66 years | Volume = NR | Standard of care | Cure rate | 100 |
Titres = NR | Mortality | ||||
ChiCTR2000030627 [China] | Severely ill/critically ill | Volume = NR | Standard of care | Temperature control | 30 |
Titres = NR | |||||
ChiCTR2000030702 [China] | Hospitalised patients | Volume = NR | Standard of care | Time to clinical recovery after randomisation | 50 |
Titres = NR | |||||
ChiCTR2000030929 [China] | Severely ill adults less than 70 years | Volume = NR | Ordinary plasma | 2-point improvement in clinical symptoms in a 6-point scale | 60 |
Titres = NR | |||||
EUCTR2020-001310-38 [Germany] | Severely ill/critically ill adults less than 75 years | Volume = up to 960 ml | Standard of care | Composite endpoint: - Survival and no longer fulfilling criteria of severe COVID-19 within 21 days after randomisation | 120 |
Titres = NR | |||||
IRCT20200310046736N1 [Iran] | Adult (20 to 45 years) | Volume = 800 ml | Standard of care | N/A | 45 |
Titres = NR | |||||
IRCT20200404046948N1 [Iran] | Severely ill/critically ill adults less than 70 years | Volume = up to 500 ml | Standard of care | 2-point improvement in clinical symptoms at 14 days | 60 |
Titres = NR | |||||
IRCT20200409047007N1 [Iran] | Critically ill adults 50–75 years with Pao2/FIO2 ratio < 300; normal IgA level and within 7 days of admission | Volume = up to 500 ml | Standard of care | 1-month mortality | 35 |
Titres = NR | |||||
IRCT20200413047056N1 [Iran] | Severely ill/critically ill adults less than 50 years | Volume = up to 400 ml | Standard of care or intravenous immunoglobulin | NR | 15(1:1:1) 3-arm study |
Titres = NR | |||||
NCT04332835 [Columbia] | Hospitalised adults less than 60 years | Volume = up to 500 ml | Hydroxychloroquine | Change in viral load | 60 |
Titres = NR | Change in antibody titres | ||||
Coadministration of hydroxychloroquine | |||||
NCT04333251 [USA] | Hospitalised adults | Volume = 2 doses | Standard of care | Reduction in oxygen and ventilation support | 115 |
Titres = > 1:64 | |||||
NCT04342182 [Netherlands] | Hospitalised adults | Volume = up to 300 ml | Standard of care | Mortality | 426 |
Titres = NR | |||||
NCT04344535 [USA] | Hospitalised adults | Volume = up to 550 ml | Standard plasma | Ventilator-free days up to day 28 | 500 |
Titres = > 1:320 | |||||
NCT04345289 [Denmark] | Hospitalised adults with pneumonia | Volume = 600 ml | Multiple interventions; adaptive platform trial | Composite endpoint of all-cause mortality or need of invasive mechanical ventilation up to 28 days | 1500 |
Titres = NR | 1:1:1:1:1:1 | ||||
NCT04345523 [Spain] | Hospitalised adults with pneumonia | Volume = 800 ml | Standard of care | WHO ordinal scale | 278 |
Titres = NR | |||||
NCT04345991 [France] | Mild severity as described in the WHO scale, within 8 days | Volume = 800 ml | Standard of care | Survival without needs of ventilator utilisation or use of immunomodulatory drugs at 14 days | 120 |
Titres = NR | |||||
NCT04346446 [India] | Severely ill/critically ill adults less than 65 years | Volume = up to 600 ml | Standard of care | Proportion of patients remaining free of mechanical ventilation at 7 days | 40 |
Titres = NR | |||||
NCT04348656 [Canada] | Hospitalised adults receiving supplemental oxygen | Volume = up to 500 ml | Standard of care | Intubation or hospital mortality within 30 days | 1200 |
Titres = NR | |||||
NCT04355767 [USA] | Adults requiring emergency department evaluation | Volume = up to 600 ml | Standard plasma | Time to disease progression at 15 days | 206 |
Titres = > 1:80 | |||||
NCT04356534 [Bahrain] | Adults > 21 years with severely ill with radiological evidence of pneumonia | Volume = up to 600 ml | Standard of care | Requirement for invasive ventilation | 40 |
Titres = > 1:80 | |||||
NCT02735707 [Multinational] | Severely ill/critically ill adults | Volume = up to 600 ml | Multiple interventions; adaptive platform trial | Days alive and outside of ICU at 21 days | 7100 platform |
Titres = > 1:64 |